Amgen said first-quarter performance supports its view that 2026 can be a "springboard year," suggesting improving fundamentals despite headwinds in the denosumab franchise. Growth products are helping offset increased competition and other losses of exclusivity, indicating a more resilient earnings trajectory ahead.
Amgen said first-quarter performance supports its view that 2026 can be a "springboard year," suggesting improving fundamentals despite headwinds in the denosumab franchise. Growth products are helping offset increased competition and other losses of exclusivity, indicating a more resilient earnings trajectory ahead.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
